netFormulary
 Report : Medicines with links to NICE 22/06/2018 13:59:11

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abiraterone 08.03.03 Non Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone acetate 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone acetate 08.03.04.02 Formulary Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regime (TA259), National Institute for Health and Care Excellence Technology Appraisal
Adalimumab 13.05.03 Formulary NICE TA 146: Adalimumab for the treatment of adults with psoriasis
Adalimumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab 11.10 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib 08.01.05 Non Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Aflibercept 11.08.02 Formulary NICE TA294: Aflibercept to treating wet age-related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 08.01 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Agomelatine 04.03.04 Formulary NICE TA231, Agomelatine for the treatment of major depressive episodes (terminated appraisal)
Alemtuzumab 08.02.03 Formulary Alemtuzumab for treating relapsing‑remitting multiple sclerosis (TA312), National Institute for Health and Care Excellence Technology Appraisal
Alirocumab 02.12 Formulary NICETA 393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine 04.09.01 Formulary NICE CG186: Multiple sclerosis in adults: management
Anakinra 10.01.03 Formulary NICE CG79 Rheumatoid arthritis in adults: management
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TA156: Anti-D in pregnant women
Apixaban tablets 02.08.02 Formulary NICE TA245: Venous thromboembolism - Apixaban (hip and knee surgery)
Apixaban tablets 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban tablets 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis (replaces TA368)
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis(replaces TA372)
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (adolescents) - aripiprazole
Autologous chondrocyte implantation 10.04 Formulary NICE TA477: Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee
Autologous chondrocyte implantation 10.04 Formulary NICE TA508: Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
Azacitidine 08.01.03 Non Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Beclometasone dipropionate 01.05.02 Formulary NICE guidelines CG166, Ulcerative colitis: Management in adults, children and young people
Bee and wasp allergen extracts 03.04.02 Formulary NICE TA246, Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Non Formulary NICE TA216: Bendamustine for CLL
Bendroflumethiazide tablets 02.02.01 Formulary NICE CG127 Hypertension
Bevacizumab 08.01.05 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bivalirudin injection 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02.03 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Boceprevir 05.03.03 Non Formulary NICE TA253: Hepatitis C (genotype 1) - boceprevir
Bortezomib 08.01.05 Non Formulary NICE TA129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Non Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Non Formulary NICE TA311: Multiple myeloma - bortezomib (induction therapy
Bortezomib 08.01.05 Non Formulary NICE TA299: Leukaemia (chronic myeloid) - bosutinib
Botulinum toxin type A 04.07.04.02 Formulary NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel 08.01.05 Non Formulary NICE TA255: Cabazitaxel for prostate cancer
Canagliflozin tablets 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin tablets 06.01.02.03 Formulary NICE TA 390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cangrelor 02.09 Formulary NICE TA351: Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy (terminated appraisal)
Cannabis extract 10.02.02 Formulary NICE CG186 Multiple sclerosis: management of multiple sclerosis in primary and secondary care
Capecitabine 08.01.03 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Non Formulary NICE TA60: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Non Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Certolizumab pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Non Formulary NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Non Formulary NICE TA172: Head and neck cancer (squamous cell carcinoma) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA176: Colorectal cancer (first line) - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA145: Head and neck cancer - cetuximab
Chronic obstructive pulmonary disease, acute infective exacerbations 27.08 Formulary NICE CG101: Chronic obstructive pulmonary disease in over 16s: diagnosis and management, June 2010
Ciclosporin 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clopidogrel tablets 02.09 Formulary NICE TA80: Acute coronary syndromes - clopidogrel
Colistimethate for nebulisation 05.01.07 Formulary NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Colistimethate inhaler 05.01.07 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Non Formulary NICE TA296: Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene
Dabigatran capsules 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran capsules 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran capsules 02.08.02 Formulary NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Daclizumab 08.02.04 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin tablets 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin tablets 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin tablets 06.01.02.03 Formulary NICE TA 390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dasatinib 08.01.05 Non Formulary NICE TA241: CML for whom treatment with imatinib has failed because of intolerance
Dasatinib 08.01.05 Non Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Denosumab 06.06.02 Formulary NICE TA265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours, October 2012
Denosumab injection 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women, October 2010
Dexamethasone 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO)
Dexamethasone 11.04.01 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone 11.04.01 Formulary NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dimethyl fumarate 08.02.04 Formulary Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (TA320), National Institute for Health and Care Excellence Technology Appraisal
Dimethyl fumarate 13.05.02 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Docetaxel 08.01.05 Non Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Non Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Dronedarone tablets 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Eculizumab 09.01.03 Formulary NICE Highly Specialised Technology HST1: Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban tablets 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban tablets 02.08.02 Formulary NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eltrombopag 09.01.04 Formulary NICE TA382: Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin tablets 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Empagliflozin tablets 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Entecavir 05.03.03 Non Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03 Non Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide 08.03.04.02 Formulary Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316), National Institute for Health and Care Excellence Technology Appraisal
Eribulin 08.01.05 Non Formulary NICE TA250: Breast cancer (advanced) - eribulin
Erlotinib 08.01.05 Non Formulary NICE TA162: Lung cancer (non-small-cell) 2nd line- erlotinib
Erlotinib 08.01.05 Non Formulary NICE TA258: Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line)
Erlotinib 08.01.05 Non Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Etanercept 13.05.03 Formulary NICE TA 103 – Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Non Formulary NICE TA295: Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor):
Everolimus 08.01.05 Non Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release injection 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults: management
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA 164: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride tablets 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: The management of lower urinary tract symptoms in men, May 2010
Fingolimod 08.02.04 Formulary Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254), National Institute for Health and Care Excellence Technology Appraisal
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Non Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone acetonide 11.04.01 Formulary Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) NICE TA301
Fulvestrant 08.03.04.01 Formulary Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239), National Institute for Health and Care Excellence Technology Appraisal
Fulvestrant 08.03.04.01 Formulary Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503), National Institute for Health and Care Excellence Technology Appraisal
Gefitinib 08.01.05 Non Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Non Formulary NICE TA25: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Non Formulary NICE TA116: Breast cancer - gemcitabine
Glatiramer Acetate 08.02.04 Formulary Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32), National Institute for Health and Care Excellence Technology Appraisal
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Golimumab 10.01.03 Formulary NICETA497: Golimumab for treating non-radiographic axial spondyloarthritis
Haloperidol 04.02.01 Formulary NICE NG10; Violence and aggression: short-term management
Helicobacter pylori, eradication 27.09 Formulary NICE CG184
Imatinib 08.01.05 Non Formulary NICE TA241: Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant)
Imatinib 08.01.05 Non Formulary NICE TA196: Gastrointestinal stromal tumours - imatinib (adjuvant): guidance
Imatinib 08.01.05 Non Formulary NICE TA70: Leukaemia (chronic myeloid) - imatinib
Imatinib 08.01.05 Non Formulary NICE TA209: Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib
Imatinib 08.01.05 Non Formulary NICE TA86: Gastro-intestinal stromal tumours (GIST) - imatinib
Imatinib 08.01.05 Non Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Imiquimod 13.07 Formulary NICE NG14 Melanoma: assessment and management
Infliximab 01.05.03 Formulary NICE Biosimilars Position Statement
Infliximab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 10.01.03 Formulary NICE Biosimilars Position Statement
Infliximab 13.05.03 Formulary NICE TA 134 – Infliximab for the treatment of adults with psoriasis
Infliximab 13.05.03 Formulary NICE Biosimilars Position Statement
Interferon Beta 08.02.04 Formulary Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32), National Institute for Health and Care Excellence Technology Appraisal
Ipilimumab 08.01.05 Non Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ivabradine tablets 02.06.03 Formulary NICE TA267: Chronic heart failure - ivabradine
Ixekizumab 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Formulary Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322), National Institute for Health and Care Excellence Technology Appraisal
Lenalidomide 08.02.04 Formulary Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (TA171), National Institute for Health and Care Excellence Technology Appraisal
Lesinurad 10.01.04 Formulary NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
Lorazepam 04.01.02 Formulary NICE CG10; Violence and aggression: short-term management
Lubiprostone 01.06.07 Formulary NICE technology appraisal TA318, Lubiprostone for treating chronic idiopathic constipation
Lumacaftor and Ivacafotor 03.07 Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Mannitol 03.07 Formulary TA266 Mannitol dry powder for inhalation for treating cystic fibrosis National Institute for Health and Clinical Excellence Technology Appraisal
Mannitol inhalation 20 Non Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Mepolizumab 03.04.02 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methotrexate 07.01.03 Formulary Ectopic pregnancy and miscarriage NICE CG154
Methyldopa tablets 02.05.02 Formulary NICE CG107: Hypertension in Pregnancy
Methylnaltrexone 01.06.06 Restricted Use NICE TA468: Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)
Mifamurtide 08.02.04 Non Formulary NICE TA235: Osteosarcoma - mifamurtide
Mifamurtide 08.02.04 Formulary Mifamurtide for the treatment of osteosarcoma (TA235), National Institute for Health and Care Excellence Technology Appraisal
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Nalmefene 04.10.01 Formulary Nalmefene for reducing alcohol consumption in people with alcohol dependence National Institute for Health and Care Excellence Technology Appraisal
Naloxegol 01.06.06 Formulary NICE TA 345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Non Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone/Bupropion 04.05.02 Formulary NICETA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Natalizumab 08.02.04 Formulary Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis (TA127) , National Institute for Health and Care Excellence Technology Appraisal
Nilotinib 08.01.05 Non Formulary NICE TA251: Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib
Nilotinib 08.01.05 Non Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Obeticholic acid 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343), National Institute for Health and Care Excellence Technology Appraisal
Obinutuzumab 08.02.03 Formulary Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472), National Institute for Health and Care Excellence Technology Appraisal
Ocriplasmin 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202), National Institute for Health and Care Excellence Technology Appraisal
Ofatumumab 08.02.03 Formulary Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344), National Institute for Health and Care Excellence Technology Appraisal
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) National Institute for Health and Clinical Excellence Technology Appraisal
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Non Formulary NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Omega-3-Acid Ethyl Esters capsules 02.12 Formulary NICE guidelines CG186: Multiple sclerosis
Oxaliplatin 08.01.05 Non Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Non Formulary NICE TA108: Breast cancer (early) - paclitaxel
Paclitaxel 08.01.05 Non Formulary NICE TA55: Ovarian cancer - paclitaxel (review)
Panitumumab 08.01.05 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib 11.08.02 Formulary NICE TA155, Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Pegloticase 10.01.04 Formulary NICE TA291: Pegloticase for treating severe debilitating chronic tophaceous gout
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pemetrexed 08.01.03 Non Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Non Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Non Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Non Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pemetrexed 08.01.03 Non Formulary NICE TA309: Lung cancer (non small cell, non squamous) - pemetrexed
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pimecrolimus 13.05.03 Formulary NICE CG 153 –Psoriasis
Pirfenidone 03.11 Formulary NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Non Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Pneumonia, community-acquired in adults 27.08 Formulary NICE CG191: Pneumonia in adults: diagnosis and management, December 2014
Pneumonia, community-acquired in children 27.08 Formulary NICE CG160: Fever in under 5s: assessment and initial management, August 2017
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (replaces TA338)
Prasugrel tablets 02.09 Formulary NICE TA317: Acute coronary syndrome - prasugrel
Progesterone 06.04.01.02 Formulary NICE NG25: Preterm labour and birth, 2015
Promethazine Hydrochloride 04.01.01 Formulary NICE NG10; Violence and aggression: short-term management
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Raloxifene Hydrochloride 06.04.01.01 Non Formulary NICE TA160: quick reference guide on osteoporosis
Raloxifene hydrochloride tablets 06.04.01.01 Formulary NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene hydrochloride tablets 06.04.01.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ranibizumab 11.08.02 Formulary Pegaptanib and ranibizumab for the treatment of age-related macular degeneration NICE TA155
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA283: Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole National Institute for Health and Care Excellence
Rituximab 08.02.03 Formulary Rituximab for aggressive non-Hodgkin’s lymphoma (TA65),National Institute for Health and Care Excellence Technology Appraisal
Rituximab 08.02.03 Formulary Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193), National Institute for Health and Care Excellence Technology Appraisal
Rituximab 08.02.03 Formulary Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174), National Institute for Health and Care Excellence Technology Appraisal
Rituximab 08.02.03 Formulary Rituximab for the treatment of relapsed or refractory stage III or IV follicular Non- Hodgkin’s lymphoma (TA137), National Institute for Health and Care Excellence Technology Appraisal
Rituximab 08.02.03 Formulary Rituximab for the first-line maintenance treatment of follicular non-Hodgkins lymphoma (TA226), National Institute for Health and Care Excellence Technology Appraisal
Rituximab 08.02.03 Formulary Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243),National Institute for Health and Care Excellence Technology Appraisal
Rituximab 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rivaroxaban tablets 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban tablets 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban tablets 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban tablets 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban tablets 02.08.02 Formulary NICE TA256: Rivaroxaban for AF
Roflumilast 03.03.03 Non Formulary NICE TA244: Chronic obstructive pulmonary disease - roflumilast
Roflumilast 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA 356 (Terminated Appraisal): Ruxolitinib for treating polycythaemia vera
Ruxolitinib 08.01.05 Formulary NICE TA368: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril/Valsartan tablets 02.05.05 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary NICE TA350 - Secukinumab for treating moderate to severe plaque psoriasis
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Tacrolimus 13.05.03 Formulary NICE CG 153 –Psoriasis - off label indication
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Non Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03 Non Formulary NICE TA252: Hepatitis C (genotype 1) - telaprevir
Telbivudine 05.03.03.01 Non Formulary NICE TA154: Hepatitis B - telbivudine
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir Disproxil 05.03.01 Non Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303), National Institute for Health and Clinical Excellence Technology Appraisal
Teriparatide injection 06.06.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary Bortezomib and thalidomide for the first line treatment of multiple myeloma (TA228), National Institute for Health and Care Excellence Technology Appraisal
Ticagrelor 02.09 Formulary NICE TA236: Acute coronary syndromes - ticagrelor
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tobramycin nebuliser solution 05.01.04 Formulary NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan tablets 06.05.02 Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Non Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Non Formulary NICE TA91: Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review)
Topotecan 08.01.05 Non Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trastuzumab 08.01.05 Non Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ustekinumab 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA 180 - Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)
Varenicline 04.10.02 Formulary NICE TA123: Varenicline NICE technology appraisal | Issued July 2007
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib 08.01.05 Non Formulary NICE TA176: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Vemurafenib 08.01.05 Non Formulary NICE TA269: Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib
Verteporfin 11.08.02 Formulary NICE TA68, Guidance on the use of photodynamic therapy for age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vortioxetine 04.03.04 Formulary NICE TA367: Vortioxetine for treating major depressive episodes
Zaleplon 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Pan Mersey Area Prescribing Committee